Merozan Dosage/Direction for Use

Adults: The dosage and duration of therapy shall be established depending on type and severity of infection and the condition of the patient. The recommended daily dosage is as follows: 500 mg IV every 8 hours in the treatment of pneumonia, urinary tract infections, gynaecological infections such as endometritis and pelvic inflammatory disease, skin and skin structure infections.
1 g IV every 8 hours in the treatment of nosocomial pneumonias, peritonitis, presumed infections in neutropenic patients and septicaemia.
In meningitis and in lung infections in patients with cystic fibrosis, doses of 2 g every 8 hours are recommended.
As with other antibiotics, particular caution is recommended in using meropenem as monotherapy in critically ill patients with known or suspected Pseudomonas aeruginosa lower respiratory tract infection.
Regular susceptibility testing is recommended when treating Pseudomonas aeruginosa infection.
Meropenem (Merozan) should be administrated by intravenous bolus injection over approximately 5 minutes or by intravenous infusion over approximately 15-30 minutes (See Caution for Usage and Storage).
Dosage Schedule for Adults with Impaired Renal Function: Dosage should be reduced in patients with creatinine clearance less than 51 ml/min, as scheduled as follows. (See Table 2.)

Click on icon to see table/diagram/image

Meropenem is cleared by haemodialysis. If continued treatment with Meropenem (Merozan) is necessary, it is recommended that the unit dose (based on the type and severity of infection) is administered at the completion of the haemodialysis procedure to restore therapeutically effective plasma concentrations. There is no experience with the use of meropenem in patients under peritoneal dialysis.
Dosage in Adults with Hepatic Insufficiency: No dosage adjustment is necessary in patients with hepatic insufficiency (See Precautions).
Elderly Patients: No dosage adjustment is required for the elderly with normal renal function or creatinine clearance values above 50 ml/min.
Children: For children over 3 months and up to 12 years of age the recommended dose is 10 to 40 mg/kg every 8 hours depending on type and severity of infection, susceptibility of the pathogen and the condition of the patient. In children over 50 kg weight, adult dosage should be used. In neutropenic patients with fever, the recommended dose is 20 mg/kg every 8 hours. In meningitis and in cystic fibrosis, the recommended dose is 40 mg/kg every 8 hours. Meropenem (Merozan) should be administrated by intravenous bolus injection over approximately 5 minutes or by intravenous infusion over approximately 15-30 minutes. There is no experience in children with renal impairment.
Reconstitution, Compatibility and Stability: Meropenem solutions for bolus intravenous injection should be dissolved in water for injections (5 ml per 250 mg meropenem). This provides an approximate concentration of 50 mg/ml. Solutions are clear, and colourless or pale yellow. Meropenem solutions for intravenous infusion can be prepared with 50 to 200 ml of Sodium chloride 0.9% w/v or any other compatible infusion fluid (See Storage). Freshly prepared solutions are recommended, however solutions of Meropenem (Merozan) can be stored at room temperature (≤25°C) or under refrigeration (at 4°C) (See Storage). Meropenem (Merozan) should not be mixed or added to other medicines. Solutions of Meropenem (Merozan) should not be frozen.